DoMore Diagnostics welcomes Andreas Berg Storsve as our new VP Operations
Oslo, Norway - DoMore Diagnostics, a leader in cancer outcome prediction with pathology AI algorithms, is pleased to announce the appointment of Andreas Berg Storsve, PhD as VP Operations. Dr. Storsve will take a leading role in driving partnerships and business development activities forward.
Dr. Storsve joins DoMore Diagnostics from the immuno-oncology biotech Circio Holding ASA (formerly Targovax ASA), where he held the position Vice President of Business Development, Alliance Management and Intellectual Property. Prior to Circio, Dr. Storsve worked at Aker BioMarine ASA as Director R&D, responsible for Neuroscience research and partnering strategy. Dr. Storsve holds a PhD in Cognitive Neuroscience and NeuroImaging from the University of Oslo and was awarded a highly prestigious Fulbright Scholarship to work as a visiting Research Fellow at the Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital / Harvard Medical School, the world's premier research center for computational neuroscience and biomedical imaging.
“I am very pleased and happy to welcome Andreas to DoMore Diagnostics. He has a strong scientific background and a broad experience from business development generating and nurturing partnerships. These are key competencies to expand the clinical documentation of our digital biomarkers and to bring them towards commercialization. This is the third time we join forces, and I am confident that Andreas will be a valuable addition to our management team,” CEO and Co-founder Torbjørn Furuseth said.
Andreas Berg Storsve added: “I am extremely excited to join the impressive team at DoMore Diagnostics on their mission to transform personalized cancer treatment. The scientific foundation is very strong, and substantial progress has been made towards making the technology market ready. I look forward to continuing this work side-by-side with Torbjørn and the DoMore team and bring our digital biomarkers to a commercial phase, to vastly improve clincial decision making and ensure each individual cancer patient is offered the optimal course of treatment."